FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Olaf van Tellingen

Research Profile

Living Beings

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Feces

Co-author Network

Publications

TOP 3
Serena Marchetti; Roberto Mazzanti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Fan Lin; Jos H Beijnen; Levi Buil; Lisette Hoogendijk; Olaf van Tellingen
Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
T Borovski; J B Daalhuisen; V Lascano; Jan Paul Medema; Hans M Rodermond; Olaf van Tellingen; J J Verhoeff; P Beke; Martin Sprick
Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Olaf van Tellingen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Serena Marchetti; Roberto Mazzanti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Investigational new drugs 2013;31(3):800.
2013: Fan Lin; Jos H Beijnen; Levi Buil; Lisette Hoogendijk; Olaf van Tellingen
Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
European journal of cancer (Oxford, England : 1990) 2013;49(8):2059-64.
2013: T Borovski; J B Daalhuisen; V Lascano; Jan Paul Medema; Hans M Rodermond; Olaf van Tellingen; J J Verhoeff; P Beke; Martin Sprick
Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.
Oncogene 2013;32(12):1539-48.
2013: Serge A L Zander; Jos H Beijnen; Olaf van Tellingen
Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;913-914():129-36.
2012: Fan Lin; Jos H Beijnen; Gayathri Chandrasekaran; Mark C de Gooijer; Olaf van Tellingen
Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;901():9-17.
2012: Nienke A de Vries; Jan H M Schellens; Jos H Beijnen; Tessa Buckle; Jin Zhao; Olaf van Tellingen
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
Investigational new drugs 2012;30(2):443-9.
2012: Serge A L Zander; Yixian Zhang; Wendy Sol; Olaf van Tellingen; Piet Borst; Lee Greenberger; Jos Jonkers; Sven Rottenberg
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
PloS one 2012;7(9):e45248.
2011: Fan Lin; David Sherris; Jos H Beijnen; Olaf van Tellingen
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(32):3823-31.
2011: Maria L H Vlaming; Els Wagenaar; Zeliha Pala; Evita van de Steeg; Anita van Esch; Olaf van Tellingen; Alfred H Schinkel
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(8):1338-44.
2011: Evita van de Steeg; Anita van Esch; Els Wagenaar; Cornelia M M van der Kruijssen; Olaf van Tellingen; Kathryn E Kenworthy; Alfred H Schinkel
High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(2):294-301.
2010: Nienke A de Vries; Sophia W Bruggeman; Danielle Hulsman; Hilda I de Vries; John Zevenhoven; Tessa Buckle; Bob C Hamans; William P Leenders; Jos H Beijnen; Maarten van Lohuizen; Anton J M Berns; Olaf van Tellingen
Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(13):3431-41.
2010: Jan-Hendrik Beumer; N E Franke; R Tolboom; Tessa Buckle; Hilde Rosing; Luis Lopez-Lazaro; J H M Schellens; Jos H Beijnen; Olaf van Tellingen
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.
Investigational new drugs 2010;28(2):145-55.
2010: Serge A L Zander; Ariena Kersbergen; Eline van der Burg; Niels de Water; Olaf van Tellingen; Sjöfn Gunnarsdottir; Janneke E Jaspers; Marina Pajic; Anders O H Nygren; Jos Jonkers; Piet Borst; Sven Rottenberg
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Cancer research 2010;70(4):1700-10.
2010: Jurjen S Lagas; Lin Fan; Els Wagenaar; Maria L H Vlaming; Olaf van Tellingen; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(1):130-40.
2009: Maria L H Vlaming; Anita van Esch; Zeliha Pala; Els Wagenaar; Koen van de Wetering; Olaf van Tellingen; Alfred H Schinkel
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
Molecular cancer therapeutics 2009;8(12):3350-9.
2009: Robert A B van Waterschoot; Jurjen S Lagas; Els Wagenaar; Cornelia M M van der Kruijssen; Antonius E van Herwaarden; Ji-Ying Song; Rogier W Rooswinkel; Olaf van Tellingen; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
Cancer research 2009;69(23):8996-9002.
2009: Nienke A de Vries; Jos H Beijnen; Olaf van Tellingen
High-grade glioma mouse models and their applicability for preclinical testing.
Cancer treatment reviews 2009;35(8):714-23.
2009: Dick Pluim; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3549-55.
2009: Tijana Borovski; Joost J C Verhoeff; Rosemarie Ten Cate; Kate Cameron; Nienke A de Vries; Olaf van Tellingen; Dirk J Richel; Wouter R van Furth; Jan Paul Medema; Martin Sprick
Tumor microvasculature supports proliferation and expansion of glioma-propagating cells.
International journal of cancer. Journal international du cancer 2009;125(5):1222-30.
2009: Jame Abraham; Maureen Edgerly; Richard Wilson; Clara Chen; Ann Rutt; Susan Bakke; Rob Robey; Andrew Dwyer; Barry Goldspiel; FRANK BALIS; Olaf van Tellingen; Susan E Bates; Tito Fojo
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3574-82.
2009: Maria L H Vlaming; Zeliha Pala; Anita van Esch; Els Wagenaar; Dirk R de Waart; Koen van de Wetering; Cornelia M M van der Kruijssen; Ronald P J Oude Elferink; Olaf van Tellingen; Alfred H Schinkel
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3084-93.
2009: Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.
BMC cancer 2009;9():444.
2009: Jan Handrick Beumer; L Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Current clinical pharmacology 2009;4(1):38-42.
2009: T M H Niers; Lois W Brüggemann; Clara P W Klerk; Femke J M Muller; Tessa Buckle; Pieter H Reitsma; Dick J Richel; C Arnold Spek; Olaf van Tellingen; Cornelis J F Van Noorden
Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung.
Clinical & experimental metastasis 2009;26(3):171-8.
2008: Serena Marchetti; Nienke A de Vries; Tessa Buckle; Maria J Bolijn; Monique van Eijndhoven; Jos H Beijnen; Roberto Mazzanti; Olaf van Tellingen; Jan H M Schellens
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Molecular cancer therapeutics 2008;7(8):2280-7.
2008: Stephan A Veltkamp; Dick Pluim; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(8):1606-15.
2008: Giulio Gambarota; William P J Leenders; Cathy Maass; Pieter Wesseling; B van der Kogel; Olaf van Tellingen; Arend Heerschap
Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI.
British journal of cancer 2008;98(11):1784-9.
2008: An Claes; Giulio Gambarota; Bob Hamans; Olaf van Tellingen; Pieter Wesseling; Cathy Maass; Arend Heerschap; William P J Leenders
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
International journal of cancer. Journal international du cancer 2008;122(9):1981-6.
2008: Riejanne Seigers; Sanne B Schagen; Wieteke Beerling; Willem Boogerd; Olaf van Tellingen; Frits S A M van Dam; Jaap M Koolhaas; Bauke Buwalda
Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat.
Behavioural brain research 2008;186(2):168-75.
2007: Serena Marchetti; Roos L Oostendorp; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Alfred H Schinkel; Richard Versace; Jos H Beijnen; Roberto Mazzanti; Jan H Schellens
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Molecular cancer therapeutics 2007;6(12 Pt 1):3307-13.
2007: Antonius E van Herwaarden; Els Wagenaar; Cornelia M M van der Kruijssen; Robert A B van Waterschoot; Johan W Smit; Ji-Ying Song; Martin van der Valk; Olaf van Tellingen; José W A van der Hoorn; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
The Journal of clinical investigation 2007;117(11):3583-92.
2007: Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6440-9.
2007: Nienke A de Vries; Mariët Ouwehand; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.
Biomedical chromatography : BMC 2007;21(11):1191-200.
2007: Sophia W M Bruggeman; Danielle Hulsman; Ellen Tanger; Tessa Buckle; Marleen Blom; John Zevenhoven; Olaf van Tellingen; Maarten van Lohuizen
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
Cancer cell 2007;12(4):328-41.
2007: Sven Rottenberg; Anders O H Nygren; Marina Pajic; Fijs W B van Leeuwen; Ingrid van der Heijden; Koen van de Wetering; Xiaoling Liu; Karin E de Visser; Kenneth G Gilhuijs; Olaf van Tellingen; Jan P Schouten; Jos Jonkers; Piet Borst
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(29):12117-22.
2007: Clara P W Klerk; Renée M Overmeer; T M H Niers; Henri H Versteeg; Dick J Richel; Tessa Buckle; Cornelis J F Van Noorden; Olaf van Tellingen
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals.
BioTechniques 2007;43(1 Suppl):7-13, 30.
2007: Jan-Hendrik Beumer; Tessa Buckle; Mariët Ouwehand; Niels E F Franke; Luis Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Investigational new drugs 2007;25(1):1-7.
2006: E Marleen Kemper; William P J Leenders; Benno Küsters; Scott Lyons; Tessa Buckle; Arend Heerschap; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3294-303.
2006: Jurjen S Lagas; Maria L H Vlaming; Olaf van Tellingen; Els Wagenaar; Robert Jansen; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6125-32.
2006: Nienke A de Vries; Jos H Beijnen; Willem Boogerd; Olaf van Tellingen
Blood-brain barrier and chemotherapeutic treatment of brain tumors.
Expert review of neurotherapeutics 2006;6(8):1199-209.
2006: Maria L H Vlaming; K Mohrmann; Els Wagenaar; Dirk R de Waart; Ronald P J Oude Elferink; Jurjen S Lagas; Olaf van Tellingen; Liia D Vainchtein; Hilde Rosing; Jos H Beijnen; J H M Schellens; Alfred H Schinkel
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(1):319-27.
2006: Rogier R Press; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Cancer chemotherapy and pharmacology 2006;57(6):819-25.
2005: Maarten Huisman; Aniska A Chhatta; Olaf van Tellingen; Jos H Beijnen; Alfred H Schinkel
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
International journal of cancer. Journal international du cancer 2005;116(5):824-9.
2005: Heleen A Bardelmeijer; Arjan B G H Roelofs; Michel J X Hillebrand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Metabolism of docetaxel in mice.
Cancer chemotherapy and pharmacology 2005;56(3):299-306.
2005: E E M Brouwers; Matthijs M Tibben; Markus Joerger; Olaf van Tellingen; Hilde Rosing; J H M Schellens; Jos H Beijnen
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2005;382(7):1484-90.
2005: Pauline Breedveld; Dick Pluim; Greta Cipriani; peter wielinga; Olaf van Tellingen; Alfred H Schinkel; Jan H M Schellens
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Cancer research 2005;65(7):2577-82.
2005: Olaf van Tellingen; Heleen A Bardelmeijer; Tessa Buckle; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens
Cannulation of the jugular vein in mice.
Laboratory animals 2005;39(1):130.
2004: Ellen Stokvis; Mariët Ouwehand; L G A H Nan; E Marleen Kemper; Olaf van Tellingen; Hilde Rosing; Jos H Beijnen
A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(12):1506-12.
2004: Pauline Breedveld; Noam Zelcer; Dick Pluim; Ozgür Sönmezer; Matthijs M Tibben; Jos H Beijnen; Alfred H Schinkel; Olaf van Tellingen; Piet Borst; Jan H M Schellens
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Cancer research 2004;64(16):5804-11.
2004: E Marleen Kemper; Willem Boogerd; Ingrid Thuis; Jos H Beijnen; Olaf van Tellingen
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Cancer treatment reviews 2004;30(5):415-23.
2004: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Investigational new drugs 2004;22(3):219-29.
2004: E Marleen Kemper; Marcel Verheij; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1269-74.
2004: E Marleen Kemper; Cindy Cleypool; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Cancer chemotherapy and pharmacology 2004;53(2):173-8.
2004: H J G Desirée van den Bongard; E Marleen Kemper; Olaf van Tellingen; Hilde Rosing; Ron A A Mathôt; Jan H M Schellens; Jos H Beijnen
Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.
Analytical biochemistry 2004;324(1):11-5.
2003: E Marleen Kemper; Mariët Ouwehand; Jos H Beijnen; Olaf van Tellingen
Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;798(1):63-8.
2003: Olaf van Tellingen; Tessa Buckle; johan jonker; Martin van der Valk; Jos H Beijnen
P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.
British journal of cancer 2003;89(9):1776-82.
2003: Heleen A Bardelmeijer; Tessa Buckle; Mariët Ouwehand; Jos H Beijnen; J H M Schellens; Olaf van Tellingen
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.
Laboratory animals 2003;37(3):181-7.
2003: E Marleen Kemper; A Erik van Zandbergen; Cindy Cleypool; Henk A Mos; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2849-55.
2003: John D Allen; Sonja C Van Dort; Marije Buitelaar; Olaf van Tellingen; Alfred H Schinkel
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Cancer research 2003;63(6):1339-44.
2003: Heleen A Bardelmeijer; Ingrid A M Oomen; Michel J X Hillebrand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Metabolism of paclitaxel in mice.
Anti-cancer drugs 2003;14(3):203-9.
2003: Serge van Ruth; Olaf van Tellingen; Catharina M Korse; Vic J Verwaal; Frans A N Zoetmulder
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.
Anti-cancer drugs 2003;14(1):57-65.
2002: Heleen A Bardelmeijer; Mariët Ouwehand; Tessa Buckle; Maarten Huisman; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Cancer research 2002;62(21):6158-64.
2002: H J G Desirée van den Bongard; Ron A A Mathôt; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Cancer chemotherapy and pharmacology 2002;50(1):16-24.
2002: John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Molecular cancer therapeutics 2002;1(6):417-25.
2002: Heleen A Bardelmeijer; Mariët Ouwehand; Mirte M Malingré; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Cancer chemotherapy and pharmacology 2002;49(2):119-25.
2001: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Mariët Ouwehand; Heleen A Bardelmeijer; Hilde Rosing; FJ Koopman; Margaret Schot; Wim W ten Bokkel Huinink; Jos H Beijnen
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; J H M Schellens; Olaf van Tellingen
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):201-6.
2001: E Marleen Kemper; B Jansen; Kenneth Brouwer; J H M Schellens; Jos H Beijnen; Olaf van Tellingen
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):135-43.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: M Crul; H J G Desirée van den Bongard; Matthijs M Tibben; Olaf van Tellingen; G Sava; J H M Schellens; Jos H Beijnen
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2001;369(5):442-5.
2000: J H M Schellens; Mirte M Malingré; C M F Kruijtzer; Heleen A Bardelmeijer; Olaf van Tellingen; A H Schinkel; Jos H Beijnen
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;12(2):103-10.
2000: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Hilde Rosing; FJ Koopman; K Duchin; Wim W Ten Bokkel Huinink; M Swart; Jos H Beijnen
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Anti-cancer drugs 2000;11(10):813-20.
2000: Heleen A Bardelmeijer; Jos H Beijnen; Kenneth Brouwer; Hilde Rosing; Willem Nooijen; J H M Schellens; Olaf van Tellingen
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: Jetske M Meerum Terwogt; Olaf van Tellingen; VR Nannan Panday; manon huizing; J H M Schellens; Wim W ten Bokkel Huinink; M U Boschma; Giuseppe Giaccone; Cindy Veenhof; Jos H Beijnen
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Heleen A Bardelmeijer; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Investigational new drugs 2000;18(3):231-41.
2000: Mirte M Malingré; JM Terwogt; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W Ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
Phase I and pharmacokinetic study of oral paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2468-75.
2000: J van Asperen; Olaf van Tellingen; Jos H Beijnen
The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(3):264-7.
1999: Jetske M Meerum Terwogt; Mirte M Malingré; Jos H Beijnen; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Olaf van Tellingen; M Swart; J H M Schellens
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: Johan W Smit; Maarten Huisman; Olaf van Tellingen; Hugh R Wiltshire; Alfred H Schinkel
Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
The Journal of clinical investigation 1999;104(10):1441-7.
1999: Olaf van Tellingen; Jos H Beijnen; Jaap Verweij; E J Scherrenburg; Willem Nooijen; Alex Sparreboom
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: Olaf van Tellingen; manon huizing; VR Panday; J H M Schellens; Willem Nooijen; Jos H Beijnen
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: Rolf W Sparidans; J Jantina Kettenes-van den Bosch; Olaf van Tellingen; B Nuyen; RE Henrar; José Jimeno; Glynn Faircloth; Pablo Floriano; K L Rinehart; Jos H Beijnen
Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.
Journal of chromatography. B, Biomedical sciences and applications 1999;729(1-2):43-53.
1999: J van Asperen; Olaf van Tellingen; Alfred H Schinkel; Jos H Beijnen
Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.
The Journal of pharmacology and experimental therapeutics 1999;289(1):329-33.
1999: Ahmad Awada; Cornelis J A Punt; Martine J Piccart; Olaf van Tellingen; L Van Manen; Joseph Kerger; Y Groot; Jantien Wanders; Jaap Verweij; D J Wagener
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.
British journal of cancer 1999;79(9-10):1454-61.
1999: R van Gijn; Olaf van Tellingen; E Haverkate; J Jantina Kettenes-van den Bosch; Auke Bult; Jos H Beijnen
Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.
Investigational new drugs 1999;17(1):29-41.
1999: J van Asperen; Olaf van Tellingen; F Tijssen; Alfred H Schinkel; Jos H Beijnen
Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
British journal of cancer 1999;79(1):108-13.
1999: R van Gijn; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; Jan B Vermorken; Olaf van Tellingen; Hilde Rosing; LJ van Warmerdam; Jos H Beijnen
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1998: Olaf van Tellingen; M Kemper; F Tijssen; J van Asperen; Willem Nooijen; Jos H Beijnen
High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):251-7.
1998: J van Asperen; Olaf van Tellingen; Martin van der Valk; M Rozenhart; Jos H Beijnen
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2293-7.
1998: VR Panday; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Michel J X Hillebrand; Ria Dubbelman; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: J van Asperen; Olaf van Tellingen; Jos H Beijnen
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):129-43.
1998: J van Asperen; Olaf van Tellingen; Jos H Beijnen
The pharmacological role of P-glycoprotein in the intestinal epithelium.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(6):429-35.
1998: Olaf van Tellingen; Willem Nooijen; L J Schaaf; Martin van der Valk; J van Asperen; RE Henrar; Jos H Beijnen
Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
Cancer research 1998;58(11):2410-6.
1998: Paul van de Vaart; Nine van der Vange; Frans A N Zoetmulder; A R van Goethem; Olaf van Tellingen; Wim W ten Bokkel Huinink; Jos H Beijnen; Harry Bartelink; Adrian C Begg
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(1):148-54.
1998: Olaf van Tellingen; Cornelis J A Punt; Ahmad Awada; D J Wagener; Martine J Piccart; Y Groot; L J Schaaf; RE Henrar; Willem Nooijen; Jos H Beijnen
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
Cancer chemotherapy and pharmacology 1998;41(5):377-84.
1998: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; J H Beijnen
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Anti-cancer drugs 1998;9(1):1-17.
1997: J van Asperen; U Mayer; Olaf van Tellingen; Jos H Beijnen
The functional role of P-glycoprotein in the blood-brain barrier.
Journal of pharmaceutical sciences 1997;86(8):881-4.
1997: Alfred H Schinkel; U Mayer; Els Wagenaar; CA Mol; Liesbeth Van Deemter; J J Smit; Martin van der Valk; Arie Voordouw; Hergen Spits; Olaf van Tellingen; J M Zijlmans; W E Fibbe; Piet Borst
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(8):4028-33.
1997: Alex Sparreboom; J van Asperen; U Mayer; Alfred H Schinkel; J W Smit; D K Meijer; Piet Borst; Willem Nooijen; Jos H Beijnen; Olaf van Tellingen
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
1997: J van Asperen; Olaf van Tellingen; Alex Sparreboom; Alfred H Schinkel; Piet Borst; Willem Nooijen; Jos H Beijnen
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
1997: Olaf van Tellingen; Willem Boogerd; Willem Nooijen; Jos H Beijnen
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.
Cancer chemotherapy and pharmacology 1997;40(4):330-4.
1996: I Wolff; K Bench; Jos H Beijnen; U Bruntsch; Franco Cavalli; J de Jong; Y Groot; Olaf van Tellingen; Jantien Wanders; Cristiana Sessa
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1717-23.
1996: J van Asperen; Alfred H Schinkel; Jos H Beijnen; Willem Nooijen; Piet Borst; Olaf van Tellingen
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Journal of the National Cancer Institute 1996;88(14):994-9.
1996: Ronald de Wit; Jos H Beijnen; Olaf van Tellingen; J H M Schellens; MM de Boer-Dennert; Jaap Verweij
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: Alex Sparreboom; Olaf van Tellingen; manon huizing; Willem Nooijen; Jos H Beijnen
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
1996: Alex Sparreboom; Olaf van Tellingen; E J Scherrenburg; J J Boesen; manon huizing; Willem Nooijen; C Versluis; J H Beijnen
Isolation, purification and biological activity of major docetaxel metabolites from human feces.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):655-8.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
1996: Olaf van Tellingen; M T Kuck; L T Vlasveld; Sjoerd Rodenhuis; Willem Nooijen; Jos H Beijnen
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
Cancer chemotherapy and pharmacology 1996;38(4):387-90.
1995: manon huizing; Alex Sparreboom; Hilde Rosing; Olaf van Tellingen; HERBERT PINEDO; Jos H Beijnen
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;674(2):261-8.
1995: R van Gijn; E Havik; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jos H Beijnen
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: LJ van Warmerdam; Olaf van Tellingen; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; R A Maes; J H Bijnen
Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?
Therapeutic drug monitoring 1995;17(5):465-70.
1995: G J Zaman; Jan Lankelma; Olaf van Tellingen; Jos H Beijnen; H Dekker; Coen C Paulusma; Ronald P J Oude Elferink; F Baas; Piet Borst
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(17):7690-4.
1995: R van Gijn; Olaf van Tellingen; J J de Clippeleir; Michel J X Hillebrand; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; S Schwertz; P Graf; Jos H Beijnen
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
1995: Alex Sparreboom; manon huizing; J J Boesen; Willem Nooijen; Olaf van Tellingen; Jos H Beijnen
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
1994: Olaf van Tellingen
Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.
Pharmacy world & science : PWS 1994;16(3):164-6.
1994: Alfred H Schinkel; J J Smit; Olaf van Tellingen; Jos H Beijnen; Els Wagenaar; Liesbeth Van Deemter; CA Mol; Martin van der Valk; Els C Robanus-Maandag; Hein te Riele
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.
Cell 1994;77(4):491-502.
1994: Olaf van Tellingen; E M Pels; RE Henrar; L J Schaaf; G E Padbury; Jos H Beijnen; Willem Nooijen
Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.
Journal of chromatography 1994;652(1):51-8.
1994: Olaf van Tellingen; A L Sonneveldt; Jos H Beijnen; Willem Nooijen; J Jantina Kettenes-van den Bosch; C Versluis; Auke Bult
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1994;33(5):425-34.
1994: LJ van Warmerdam; Sjoerd Rodenhuis; Olaf van Tellingen; R A Maes; Jos H Beijnen
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
Cancer chemotherapy and pharmacology 1994;35(2):179-81.
1994: J H Sips; Olaf van Tellingen; Willem Nooijen; Sjoerd Rodenhuis; W J Ten Bokkel Huinink; Jos H Beijnen
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Cancer chemotherapy and pharmacology 1994;35(2):144-8.
1993: R van Gijn; M J De Graaff-Teulen; Olaf van Tellingen; Jos H Beijnen
Chemical stability of the new antitumour agent intoplicine in infusion fluids.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1353-6.
1993: R van Gijn; S Kuijs; Hilde Rosing; A C Dubbelman; Olaf van Tellingen; Wim W ten Bokkel Huinink; HERBERT PINEDO; Jos H Beijnen
Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1345-8.
1993: R van Gijn; Hilde Rosing; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jan B Vermorken; A J Liefting; R Bruno; HERBERT PINEDO; Jos H Beijnen
Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;614(2):299-306.
1993: Olaf van Tellingen; Jos H Beijnen; Willem Nooijen; Auke Bult
Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
Cancer research 1993;53(9):2061-5.
1993: Olaf van Tellingen; A V Kuijpers; Jos H Beijnen; Willem Nooijen; Auke Bult
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
Investigational new drugs 1993;11(2-3):141-50.
1993: Olaf van Tellingen; Jos H Beijnen; Willem Nooijen; Auke Bult
Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1993;32(4):286-92.
1992: David Burger; Hilde Rosing; R van Gijn; Pieter L Meenhorst; Olaf van Tellingen; Jos H Beijnen
Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;584(2):239-47.
1992: Olaf van Tellingen; J H Sips; Jos H Beijnen; Auke Bult; Willem Nooijen
Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).
Anticancer research 1992;12(5):1699-715.
1992: Olaf van Tellingen; J H Sips; Jos H Beijnen; Jan H Schornagel; W J Nooyen
Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,6,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;576(1):158-62.
1992: Olaf van Tellingen; Jos H Beijnen; R Baurain; Wim W ten Bokkel Huinink; H R van der Woude; W J Nooyen
Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;574(2):293-8.
1992: Olaf van Tellingen; A Kuijpers; Jos H Beijnen; M R Baselier; J T Burghouts; W J Nooyen
Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;573(2):328-32.
1991: Olaf van Tellingen; Jos H Beijnen; R Baurain; Wim W ten Bokkel Huinink; H R van der Woude; W J Nooyen
High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids.
Journal of chromatography 1991;553(1-2):47-53.
1991: M J Deurloo; W Kop; Olaf van Tellingen; Harry Bartelink; Adrian C Begg
Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.
Cancer chemotherapy and pharmacology 1991;27(5):347-53.
1991: P M Terheggen; BG Floot; E L Lempers; Olaf van Tellingen; Adrian C Begg; L den Engelse
Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Cancer chemotherapy and pharmacology 1991;28(3):185-91.
1991: H M Oosterkamp; L T Vlasveld; Jantien Wanders; Jos H Beijnen; Olaf van Tellingen; A C Dubbelman; G P Simonetti; H R Franklin; Jan B Vermorken; Wim W ten Bokkel Huinink
Phase I study of vintriptol, a tryptophan ester of vinblastine.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1222-6.
1991: Olaf van Tellingen; Jos H Beijnen; W J Nooyen
Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):1077-82.
1990: Olaf van Tellingen; H R van der Woude; Jos H Beijnen; K S Rao; Wim W ten Bokkel Huinink; W J Nooyen
High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol.
Journal of chromatography 1990;529(2):329-38.
1990: Olaf van Tellingen; Jos H Beijnen; H R van der Woude; Peter Bruning; W J Nooyen
High-performance liquid chromatographic method for the analysis of 10-ethyl-10-deaza-aminopterin and metabolites in plasma.
Journal of chromatography 1990;529(1):135-43.
1990: Olaf van Tellingen; Jos H Beijnen; H R van der Woude; R Baurain; Wim W ten Bokkel Huinink; W J Nooyen
Bio-analysis of N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, methane sulphonate (VileE) by high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):1029-31.
1989: Olaf van Tellingen; H R van der Woude; Jos H Beijnen; C J van Beers; W J Nooyen
Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids.
Journal of chromatography 1989;488(2):379-88.
1987: Olaf van Tellingen; Johannes M G Bonfrer; W J Nooyen; Peter Bruning
Improved method for the quantification of aminoglutethimide in urine samples.
Clinica chimica acta; international journal of clinical chemistry 1987;169(1):99-108.